igf 1 lr3 que es IGF-1 1mg Research Vial — Long Acting IGF-1 Receptor Grade IGF-1 LR3 -
Description
Evidence boundary The published trial record describes safety more clearly than efficacy
A surrogate endpoint may reduce the duration length and cost of clinical trials and be a better indicator of drug efficacy with hematological indices better served as secondary endpoints
Tumor targeting peptides are efficient vehicles for selective delivery of high dose of chemotherapeutic drugs or diagnostic agents to tumor sites while sparing normal tissues
Rotate injection sites systematically to prevent lipohypertrophy
